Dermata Therapeutics, Inc. Quarterly report pursuant to Section 13 or 15(d)

Balance Sheet Details (Tables)

9 Months Ended

Sep. 30, 2022

	September 30,		December 31,
	2022		2021
Prepaid expenses and other current assets
Prepaid insurance	$	806,661	$	769,416
Prepaid research and development costs		52,100		-
Prepaid other		36,413		-
Interest receivable		12,893		-
Deferred offering costs		-		55,718
Total prepaid expenses and other current assets	$	908,067	$	825,134

Accrued and other current liabilities
Accrued research and development costs	$	633,293	$	235,384
Accrued compensation and benefits		317,089		766,207
Accrued legal fees		13,801		-
Accrued board compensation		55,625		-
Accrued other		773		-
Total accrued and other current liabilities	$	1,020,581	$	1,001,591